Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Common Equity (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Common Equity readings, the most recent being $199.7 million for Q4 2025.

  • Quarterly Common Equity rose 37.43% to $199.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $199.7 million through Dec 2025, up 37.43% year-over-year, with the annual reading at $199.7 million for FY2025, 37.43% up from the prior year.
  • Common Equity hit $199.7 million in Q4 2025 for Oramed Pharmaceuticals, down from $203.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $203.3 million in Q3 2025 and bottomed at $49.4 million in Q1 2021.
  • Average Common Equity over 5 years is $148.8 million, with a median of $153.1 million recorded in 2022.
  • The largest annual shift saw Common Equity skyrocketed 503.13% in 2021 before it fell 15.58% in 2025.
  • Oramed Pharmaceuticals' Common Equity stood at $170.2 million in 2021, then fell by 11.17% to $151.2 million in 2022, then rose by 7.76% to $162.9 million in 2023, then decreased by 10.77% to $145.3 million in 2024, then skyrocketed by 37.43% to $199.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Common Equity are $199.7 million (Q4 2025), $203.3 million (Q3 2025), and $153.6 million (Q2 2025).